Prosecution Insights
Last updated: July 28, 2026
Application No. 17/179,931

COMPOSITIONS FOR DELIVERY OF CARGO TO CELLS

Final Rejection §103
Filed
Feb 19, 2021
Priority
Mar 02, 2018 — provisional 62/637,705 +3 more
Examiner
BURKHART, MICHAEL D
Art Unit
1638
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sixfold Bioscience Ltd.
OA Round
2 (Final)
62%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
74%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
516 granted / 826 resolved
+2.5% vs TC avg
Moderate +11% lift
Without
With
+11.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
40 currently pending
Career history
869
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
34.8%
-5.2% vs TC avg
§102
10.6%
-29.4% vs TC avg
§112
22.2%
-17.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 826 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims 21-26, 29, 32-39 is/are rejected under 35 U.S.C. 103 as being unpatentable over Shapiro et al (WO 2015/042101, of record, reference below is to the US patent publication of the WO document, US 2017/0121708, also of record) in view of Kim et al (Sci Rep. 2015, of record). Claims 21-26, 29-39 is/are rejected under 35 U.S.C. 103 as being unpatentable over Shapiro et al (WO 2015/042101, of record) in view of Kim et al (Sci Rep. 2015 of record) and Stephan et al (US PGPUB 2016/0145348, of record). These rejections are maintained for reasons made of record and for reasons set forth below. Response to Arguments Applicant's arguments filed 9/29/2025 have been fully considered but they are not persuasive. Applicants essentially assert that Shapiro et al is directed to RNA-DNA hybrids, not DNA nanoparticles as in the instant claims. Such is not convincing. The instant claims only require “DNA”, and do not remove RNA/DNA hybrids from the claimed scope Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Burkhart whose telephone number is (571)272-2915. The examiner can normally be reached M-F 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Tracy Vivlemore can be reached at 571 272-2914. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Michael Burkhart Examiner Art Unit 1633 /MICHAEL D BURKHART/Primary Examiner, Art Unit 1638
Read full office action

Prosecution Timeline

Feb 19, 2021
Application Filed
Mar 27, 2025
Non-Final Rejection mailed — §103
Sep 29, 2025
Response Filed
Jan 14, 2026
Final Rejection mailed — §103
Jul 25, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12679881
SYNTHETIC PATHWAY ACTIVATORS
1y 2m to grant Granted Jul 14, 2026
Patent 12672643
GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOF
3y 6m to grant Granted Jul 07, 2026
Patent 12655477
DNA VACCINES
4y 0m to grant Granted Jun 16, 2026
Patent 12655415
NANOCAGED ENZYMES WITH ENHANCED CATALYTIC ACTIVITY AND INCREASED STABILITY
2y 8m to grant Granted Jun 16, 2026
Patent 12637497
AAV CAPSID CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
4y 7m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
62%
Grant Probability
74%
With Interview (+11.1%)
3y 3m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 826 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month